Cargando…
Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial
BACKGROUND: Bedaquiline, an antimycobacterial agent approved for drug-resistant tuberculosis, is metabolized by CYP3A4, an hepatic enzyme strongly induced by rifampin, an essential part of drug-sensitive tuberculosis treatment. We examined the pharmacokinetic interactions of bedaquiline plus either...
Autores principales: | Wallis, Robert S., Good, Caryn E., O’Riordan, Mary A., Blumer, Jeffrey L., Jacobs, Michael R., Griffiss, J. McLeod, Healan, Amanda, Salata, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931679/ https://www.ncbi.nlm.nih.gov/pubmed/29718967 http://dx.doi.org/10.1371/journal.pone.0196756 |
Ejemplares similares
-
Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
por: Magee, Kevin P., et al.
Publicado: (1996) -
Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers
por: Yendewa, George A., et al.
Publicado: (2022) -
TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug’s Uncoupler Activity
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020) -
Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin
por: Alnewais, Marwah E., et al.
Publicado: (2023) -
rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis
por: Li, Ma-Chao, et al.
Publicado: (2022)